Alnylam Pharmaceuticals

Cambridge,  MA 
United States
  • Booth: 367, MS5

Alnylam is developing an entirely new class of medicines based on the breakthrough discovery in biology known as RNA interference, or RNAi. Alnylam believes that RNAi therapeutics is a promising approach to silence disease-causing genes, and represent an opportunity to transform the treatment of many diseases.